After Andrew left the JPMorgan Meeting in San Francisco we spoke about the near future of diabetes care for Type 2 patients and he said he thought it will be in GLP-1 agonist therapy. With over 16 new GLP-1s in second or third phase development it is no wonder that this class of drugs has been getting so much attention. And our readers seemed to be tuned into this as well as several of you have requested more information on these promising drugs and why researchers are so excited about them. This week’s Homerun Slides focus on how the GLP-Agonists work.
$14.99 for gold; $9.99 for silver; our Disaster Averted this week focuses on how the simple purchase of a cheap diabetes ID bracelet can keep your insulin-using patient out of the ER.
Hyperosmolar Hyperglycemic Nonketotic Syndrome is an acute metabolic complication that can be life-threatening. Learn more about this by reading this week’s Clinical Gem.